金黄色葡萄球菌菌血症持续时间与不良结局的风险阈值
该多中心前瞻性观察研究纳入884例成人金黄色葡萄球菌菌血症(SAB)住院患者,按菌血症持续时间分为短(1-2天)、中(3-6天)和长(≥7天)三组。结果显示菌血症每持续一天,死亡相对风险为1.16(95%CI 1.10-1.22;P<.0001),ROC分析提示风险从第3天起显著增加。延迟感染源控制而非抗菌药物选择与菌血症延长和不良结局显著相关。
要点
- 菌血症每多持续一天,死亡相对风险增加16%(RR 1.16,95%CI 1.10-1.22)。
- ROC分析显示死亡风险从菌血症第3天起显著增加。
- 延迟感染源控制而非抗菌药物种类与菌血症延长和不良结局相关。
核心结论
- SAB最佳管理应尽早实现细菌清除,以最小化每多一天阳性血培养带来的增量死亡风险。
研究设计与样本
- 多中心、前瞻性、观察性研究,纳入884例成人住院SAB患者,按菌血症持续时间分组比较危险因素与结局。
主要发现
- 884例中63%为短程(1-2天)、28%为中程(3-6天)、9%为长程(≥7天)菌血症。
- 长程组耐甲氧西林SAB比例最高(P<.0001)。
- 长程和中程组感染源控制手术时间较短路组延迟(3.5 vs 3 vs 1天,P<.0001)。
- 转移性并发症、住院时间和30天死亡率随菌血症持续时间增加而逐步恶化(P<.0001)。
- 菌血症每持续一天死亡相对风险为1.16(95%CI 1.10-1.22;P<.0001),ROC分析显示风险从3天起显著增加。
关键数值与推荐
- 菌血症持续时间分组:短程1-2天、中程3-6天、长程≥7天。
- 抗菌药物选择对菌血症持续时间无显著影响。
临床怎么用
- 应尽早实现细菌清除,缩短菌血症持续时间以降低死亡风险。
- 需重视并及时实施感染源控制,而非仅关注抗葡萄球菌药物选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent Staphylococcus aureus bacteremia (SAB) is defined based on varying duration in literature. The primary objective was to determine the risk of poor outcomes in relation to bacteremia duration. METHODS: Multicenter, prospective, observational study of adult hospitalized patients with SAB. Medical records were reviewed for pertinent data. Patients were grouped by bacteremia duration: short (1-2 days), intermediate (3-6 days), and prolonged (≥7 days) and compared for risk factors and outcomes. RESULTS: Of 884 patients, 63% had short, 28% intermediate, and 9% prolonged bacteremia. Overall mean age was 57 years, and 70% were male. The prolonged group had the highest proportion of methicillin-resistant SAB (P < .0001). Choice of antibiotic therapy did not significantly affect bacteremia duration; however, time to source-control procedure was delayed in the prolonged and intermediate groups compared with the short group (3.5 vs 3 vs 1 day, P < .0001). Metastatic complications, length of stay, and 30-day mortality were progressively worse as bacteremia duration increased (P < .0001). Every continued day of bacteremia was associated with a relative risk of death of 1.16 (95% confidence interval, 1.10-1.22; P < .0001), with a significant increase in risk starting at 3 days as determined by receiver operating characteristic analysis. CONCLUSIONS: Optimal management of SAB should target bacterial clearance as soon as possible to minimize incremental risk of mortality with each day of positive blood culture. Delay in source control but not type of antistaphylococcal therapy was significantly associated with prolonged bacteremia and worse outcomes.
引用
- Minejima E, Mai N, Bui N, et al. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis. 2020. PMID: 30949675. doi:10.1093/cid/ciz257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。